Exscalate Foundation Holdings
Dompe Farmaceutici Logo
    • Who We Are
      • History
      • Management Team
      • Environment, Quality & Safety
      • Ethics and Compliance
    • Where We Are
      • Manufacturing Biotech
      • Manufacturing Pharma
      • Offices
    • Discover more - About Us
    • Nerve Growth Factor
    • Pipeline
    • Disease Focus
      • Neurotrophic keratitis (NK)
      • Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
      • Atopic Kerato-conjunctivitis (AKC)
    • Exscalate
    • Discover more - Science
    • Primary & Specialty Care
      • Pain and Anti-inflammatory
      • Cold, Flu & Cough
      • Gastro
      • Cardiovascular
      • Eye, Skin & Oral Care
      • Prevention
    • Ophthalmics
    • Managed Access Programs
    • Discover more - Medicines
    • News & Announcements
    • Press Office
    • Discover more - Media
    • People & Culture
    • Join Us
    • Discover more - Careers
  • Global
  • IT
  • US

Mobile Navigation Menu

    • Who We Are
      • History
      • Management Team
      • Environment, Quality & Safety
      • Ethics and Compliance
    • Where We Are
      • Manufacturing Biotech
      • Manufacturing Pharma
      • Offices
    • Discover more - About Us
    • Nerve Growth Factor
    • Pipeline
    • Disease Focus
      • Neurotrophic keratitis (NK)
      • Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
      • Atopic Kerato-conjunctivitis (AKC)
    • Exscalate
    • Discover more - Science
    • Primary & Specialty Care
      • Pain and Anti-inflammatory
      • Cold, Flu & Cough
      • Gastro
      • Cardiovascular
      • Eye, Skin & Oral Care
      • Prevention
    • Ophthalmics
    • Managed Access Programs
    • Discover more - Medicines
    • News & Announcements
    • Press Office
    • Discover more - Media
    • People & Culture
    • Join Us
    • Discover more - Careers
  • Global
  • IT
  • US
Suggested topics:

  1. Home >
  2. Science

Science

With our research and development we target some of the highest-needing therapeutic areas

  • Nerve Growth Factor

    After seven years of challenging research, Dompé successfully engineered and manufactured the first recombinant human Nerve Growth Factor (rhNGF)

    Learn more
  • Pipeline

    Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

    Learn more
  • Disease Focus

    Redefining treatments for ophthalmic, neurological and pain-related indications through NGF and beyond. Read more on our research

    Learn more
  • Exscalate

    Our AI platform screens drugs fast, using the world’s largest chemical library for early candidate selection

    Learn more
Dompé
Pharmaco-vigilance and Vigilance Contact Privacy Policy Terms and Conditions Cookie Policy Supplier Customer Information Accessibility Whistleblowing

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00 REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. 

© 2025 Dompé. All rights reserved.

  • Global
  • IT
  • US